share_log

四環醫藥：自願公告-惠升生物研發的三款門冬胰島素產品獲國家藥監局批准上市

SIHUAN PHARM: VOLUNTARY ANNOUNCEMENT-THREE INSULIN ASPART PRODUCTS DEVELOPED BY HUISHENG BIOPHARMACEUTICAL OBTAINED DRUG REGISTRATION APPROVAL FROM NMPA

香港交易所 ·  Jan 7 23:00
Summary by Moomoo AI
四環醫藥控股集團有限公司宣布，其非全資附屬公司惠升生物製藥股份有限公司研發的三款門冬胰島素產品已獲得中國國家藥品監督管理局批准上市，用於治療糖尿病。這三款產品包括門冬胰島素注射液、門冬胰島素30注射液及門冬胰島素50注射液，均屬於國家醫保乙類（2023版）。此次批准標誌著惠升生物從研發階段進入糖尿病全產品商業化發展的新階段。門冬胰島素系列產品在中國市場具有廣泛的應用，且根據諾和諾德年報，2022年在大中華區市場收入達到人民幣59億元。惠升生物作為國內專注於糖尿病及併發症領域的生物醫藥公司，已發展成為全產業鏈生物制藥公司。四環醫藥自2001年創立，2010年在香港聯合交易所有限公司主板上市，致力於成為中國領先的醫美及生物制藥企業。
四環醫藥控股集團有限公司宣布，其非全資附屬公司惠升生物製藥股份有限公司研發的三款門冬胰島素產品已獲得中國國家藥品監督管理局批准上市，用於治療糖尿病。這三款產品包括門冬胰島素注射液、門冬胰島素30注射液及門冬胰島素50注射液，均屬於國家醫保乙類（2023版）。此次批准標誌著惠升生物從研發階段進入糖尿病全產品商業化發展的新階段。門冬胰島素系列產品在中國市場具有廣泛的應用，且根據諾和諾德年報，2022年在大中華區市場收入達到人民幣59億元。惠升生物作為國內專注於糖尿病及併發症領域的生物醫藥公司，已發展成為全產業鏈生物制藥公司。四環醫藥自2001年創立，2010年在香港聯合交易所有限公司主板上市，致力於成為中國領先的醫美及生物制藥企業。
FOUR RING PHARMACEUTICAL HOLDINGS GROUP LIMITED ANNOUNCED THAT THREE MANDARIN INSULIN PRODUCTS DEVELOPED BY ITS NON-WHOLLY OWNED SUBSIDIARY HUICHENG BIOPHARMACEUTICALS CO., LTD. HAVE BEEN APPROVED TO MARKET BY CHINA'S NATIONAL DRUG ADMINISTRATION FOR THE TREATMENT OF DIABETES. These three products, including Monton Insulin Injection, Monton Insulin 30 Injection and Monton Insulin 50 Injection, are classified under National Health Insurance Class B (2023 Edition). This approval marks a new stage in the evolution of Wellbeing from the R&D phase into the commercialization of all diabetes products. MENDON INSULIN SERIES PRODUCTS HAVE WIDE APPLICATION IN THE CHINESE MARKET, AND ACCORDING TO NORD ANNUAL REPORT, THE MARKET REVENUE IN GREATER CHINA REACHED RMB59 BILLION IN 2022. As a domestic biopharmaceutical company focused on diabetes and complications, Wellcome Biologics has developed into an industry-wide chain biopharmaceutical company. Founded in 2001 and listed on the main board of the Hong Kong Stock Exchange Limited in 2010, Four Circle Pharmaceuticals is committed to becoming a leading pharmaceutical and biopharmaceutical company in China.
FOUR RING PHARMACEUTICAL HOLDINGS GROUP LIMITED ANNOUNCED THAT THREE MANDARIN INSULIN PRODUCTS DEVELOPED BY ITS NON-WHOLLY OWNED SUBSIDIARY HUICHENG BIOPHARMACEUTICALS CO., LTD. HAVE BEEN APPROVED TO MARKET BY CHINA'S NATIONAL DRUG ADMINISTRATION FOR THE TREATMENT OF DIABETES. These three products, including Monton Insulin Injection, Monton Insulin 30 Injection and Monton Insulin 50 Injection, are classified under National Health Insurance Class B (2023 Edition). This approval marks a new stage in the evolution of Wellbeing from the R&D phase into the commercialization of all diabetes products. MENDON INSULIN SERIES PRODUCTS HAVE WIDE APPLICATION IN THE CHINESE MARKET, AND ACCORDING TO NORD ANNUAL REPORT, THE MARKET REVENUE IN GREATER CHINA REACHED RMB59 BILLION IN 2022. As a domestic biopharmaceutical company focused on diabetes and complications, Wellcome Biologics has developed into an industry-wide chain biopharmaceutical company. Founded in 2001 and listed on the main board of the Hong Kong Stock Exchange Limited in 2010, Four Circle Pharmaceuticals is committed to becoming a leading pharmaceutical and biopharmaceutical company in China.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more